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Abstract
Background: In the Western world, endometrial cancers are the most common gynaecological
neoplastic disorders among women. Initial symptoms are often vague and may be confused with
several other conditions or disorders. Thus, there is a need for an easy and reliable diagnostic tool.
The objective of this work was to identify a gene expression signature specific for endometrial
adenocarcinomas to be used for testing potential endometrial biomarkers.
Results: Changes in expression between endometrial adenocarcinomas and non-/pre-malignant
endometrium from the BDII EAC rat model were compared in cDNA microarray assays. By
employing classification analysis (Weka) on the expression data from approximately 5600 cDNA
clones and TDT analysis on genotype data, we identified a three-gene signature (Gpx3, Bgn and
Tgfb3). An independent analysis of differential expression, revealed a total of 354 cDNA clones with
significant changes in expression. Among the 10 best ranked clones, Gpx3, Bgn and Tgfb3 were
found.
Conclusion: Taken together, we present a unique data set of genes with different expression
patterns between EACs and non-/pre-malignant endometrium, and specifically we found three
genes that were confirmed in two independent analyses. These three genes are candidates for an
EAC signature and further evaluations of their involvement in EAC tumorigenesis will be
undertaken.
Background
Endometrial carcinomas (ECs) are the most frequently
occurring malignancies in the genital tract among women
in the Western world. As in most other cancer diseases,
neoplastic progression to EC is very complex, and
involves high penetrance genes as well as intricate interac-
tions of multiple low penetrance genes [1]. ECs can be
divided into two broad categories based on morphology;
Type I endometrial cancer, which accounts for approxi-
mately 70–80% of all ECs, follows the estrogen-related
pathway and frequently develops in the setting of com-
plex atypical hyperplasias as malignant precursors. The
type II category of endometrial tumors is non-
endometroid carcinomas which arise from endometrial
polyps or from endometrial intra-epithelial carcinoma.
Endometrial adenocarcinoma (EAC) is the most common
type I EC and originates from the glandular cells of the
uterus surface epithelium. Type I tumors occur pre-domi-
nantly in pre- or peri-menopausal women, whereas the
more aggressive type II tumors occur in post-menopausal
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women and carry a high mortality rate [1-3]. Successful
treatment is dependent on accurate and early diagnosis. In
EAC, however, early presenting symptoms are usually
vague and easily confused with other conditions and
hence there is a need for an easy and reliable diagnostic
tool.
Due to the genetic heterogeneity among the human pop-
ulation and the complexity of tumor etiology, it is attrac-
tive to use inbred animal model systems in studies of
carcinogenesis. The BDII/Han inbred rat model, first
described in 1987, is genetically well characterized and
has since then become a useful model for studies of
human endometrial adenocarcinoma. More than 90% of
the female BDII/Han virgins spontaneously develop EC
during their life time, where the majority of the neo-
plasms are EACs. The endometrial carcinogenesis in the
females of the BDII rat strain is hormone dependent and
represents an outstanding model for spontaneous hormo-
nal carcinogenesis. [4-6]
Genomic approaches such as gene expression profiling by
DNA microarrays, provide unprecedented tools to handle
the complexity of cancer at the transcriptional level. In the
present study, we have applied different statistical and
classification approaches on global expression data to
identify potential classifiers, i.e. sets of marker genes
whose expression profiles can be used to differentiate
between EAC tumors and non/pre-malignant endome-
trial lesions. Furthermore, we have used genotype data
from the female progenies of BDII crosses [7,8] to investi-
gate whether the genes with significantly differential
expression are associated to potential susceptibility
regions. In this study, a unique dataset has been identified
that can act as a starting point to establish a panel of
endometrial cancer biomarkers and to explore the role of
the identified genes in endometrial carcinogenesis.
Results
Significance analysis
The significance analysis of the microarrays demonstrated
890 dysregulated genes. However this number was con-
siderably reduced to 354 when applying FDR p-value
adjustment. The 50 most differentially expressed genes
were subjected to hierarchical clustering and their expres-
sions are shown in Figure 1.
Gene function classification
Out of the top 50 genes, 31 genes were found to be
involved in cellular processes commonly implicated in
human tumorigenesis (Figure 2a). As illustrated in Figure
2b, a majority of these genes were found to be involved in
more than one of these, and in some cases several, proc-
esses. For example, Tgfb2 is involved in 12 different proc-
esses commonly aberrant in tumors and Thy1 in 10.
Identification of gene classifiers
The overall classification results obtained with the models
derived by the machine learning algorithms in Weka are
summarized in Supplementary Table 1. Each of the 44
applicable algorithms was applied in 29 training and test
cycles. In each cycle, a classification was generated using
28 samples as training data and leaving out a single sam-
ple for testing (leave-one-out cross validation). The result-
ing cross-validated average classification accuracy was
97.1%. The algorithm ZeroR serves as a base-line, since it
simply classifies every sample as belonging to the majority
class, which here results in an accuracy of 59%. All algo-
rithms performed much better than the base-line, with the
majority (38 of 43 algorithms) reaching accuracies of 97%
(a single misclassification) or 100%.
For many classification algorithms the output from Weka
also includes the genes that the classifier is based on, and
for some algorithms it is possible to determine the gene
that had the most influence on the classification results.
Table 1 shows the most frequently occurring of these "top
genes", i.e. Gpx3 (9 algorithms) and Bgn (7 algorithms).
TDT analysis
The significance analysis revealed 354 genes to be differ-
entially expressed between non/pre-malignant and
endometrial samples. We choose to investigate the loca-
tions in the genome of the 50 genes with the highest dif-
ferential expression. By means of TDT analysis on samples
on the backcross progeny (n = 39), we could only identify
one gene (Tgfb3) with significant association to a suscep-
tibility region (6q31, ~65 cM) in the BN background. In
this region, all animals from crosses with the BN back-
ground that developed tumors were homozygous for the
BDII alleles. We chose to include genes in the proximity
(within 10 Mbp or a 20 cM region), which means that
there is at least 80% probability that the loci are inherited
together.
To confirm the microarray data, a semi quantitative RT-
PCR was performed for all of the selected genes in ten of
the cell lines included in the microarray experiment. The
RT-PCR confirmed the gene expressions data from the
microarray study in all measurements (Figure 3).
Discussion
Gene expression profiling, in combination with statistical
and classification methods, provides a powerful method
of analyzing the complexity of cancer etiology. Genome-
wide analysis of the expression patterns of neoplastic and
non-/pre-malignant cells provides new information
which can lead to identification of cellular pathways that
might be affected by malignant transformation. In addi-
tion, global gene expression profiling facilitates the iden-Cancer Cell International 2009, 9:12 http://www.cancerci.com/content/9/1/12
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The results from the hierarchical clustering of the 50 genes with the highest significant differential expression between normal/ pre-malignant and EAC samples Figure 1
The results from the hierarchical clustering of the 50 genes with the highest significant differential expression 
between normal/pre-malignant and EAC samples. In the significance analysis of the microarray data, 890 genes were 
found to be differentially expressed between non/pre-malignant samples and the endometrial tumors and when applying FDR, 
this number was decreased to 354 genes. Here, the 50 genes with the highest differential expression are shown.Cancer Cell International 2009, 9:12 http://www.cancerci.com/content/9/1/12
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Gene functional analysis of the 50 genes with the highest significant differential expression Figure 2
Gene functional analysis of the 50 genes with the highest significant differential expression. a) Results of the anal-
ysis of gene function revealed that 31 genes were involved in cellular functions frequently implicated in human carcinogenesis, 
such as apoptosis, proliferation etc. b) Clustering of the functional categories and the 31 identified genes, displayed that several 
of these genes are involved in several cellular processes.
Table 1: Potential marker genes most frequently occurring as the best classifiers derived by Weka.
Ensemble gene Id Gene symbol Gene name Chromosomal localization
ENSRNOG00000021809 Gpx3 Glutathione peroxidase 3 10q22
ENSRNOG00000017440 Bgn Biglycan Xq37Cancer Cell International 2009, 9:12 http://www.cancerci.com/content/9/1/12
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tification of new diagnostic markers and potential
therapeutic targets.
In the present work, we have compared the expression
patterns of EAC tumor cell lines with non-/pre-malignant
endometrial samples. In total, 28 specimens were investi-
gated, out of which 16 cell lines originated from EAC
tumors and 12 from non-/pre-malignant lesions. Based
on pathology, the tumors that developed in the N1 and F2
progenies were initially classified as EAC or other uterine
tumors (Karlsson et al. 2007). However, in some cases, no
malignant cells were detected in the removed cell mass
when pathologically characterized. These tissue samples
represent normal or pre-malignant endometrium, and
hence provide new valuable information concerning the
developmental stages during carcinogenesis. In a previous
study, we re-classified the samples predicated on the
expression patterns in combination with observed cell
morphology/physiology. In the re-classification the
expression of genes regulated by the TGF-β signaling path-
way as well as global expression data were used, and two
major groups with distinct differences in the expression
patterns were recognized [9]. One group contained mostly
samples earlier classified as EACs and only few earlier clas-
sified as non-/pre-malignant cell lines. This group was
subsequently characterized as EACs, since the morphol-
ogy and physiology of these cell lines (including those for-
merly classified as non-/pre-malignant), are in accordance
with the typical properties of malignant cells in culture.
The second group contained mostly samples previously
classified as non-/pre-malignant, and a minority of EACs.
This group was subsequently classified as non-/pre-malig-
nant samples, since all cell lines in this group shared sim-
ilar expression patterns, and displayed more or less
normal morphological/physiological characteristics when
cultured in vitro.
As expected, many genes showed differential expression
between non-/pre-malignant endometrium and endome-
trial adenocarcinomas. In total, we found 354 genes that
were significantly differentially expressed between the
groups. In Figure 1, we present a clustering of the 50 genes
with most significant differential expression between
EACs and non-/pre-malignant samples. Generally, the
genes that were found to be differentially expressed were
down-regulated in the EAC group whereas the majority of
the genes were more or less normally expressed in the
non-/pre-malignant samples. The fact that the majority of
the differentially expressed genes are down-regulated in
the tumors implies that these genes are disruptive in EAC
and may exhibit tumor suppressor features.
We also examined the gene functions of the top 50 genes
using DAVID [10], were 31 genes were found to be
involved in cellular processes known to be frequently dis-
turbed in malignant cells (Figure 2a). Thus, the results
from the gene function classification support the candi-
date gene selection from the significance analysis. The fact
that several of these genes were involved in more than one
process reflects the complexity of the cancer etiology (Fig-
ure 2b). These 31 genes could be considered a basis for an
EAC signature.
When we performed the TDT analysis on genotyping data
from the genome-wide screen with microsatellite markers,
we could pin-point one gene, transforming growth factor
beta 3, Tgfb,3 that was located in a susceptibility region
identified in progenies from backcrosses with the BN
background. Independent of tumor grade (malignant or
non-/pre-malignant cell lines), we found a significant chi-
square value from the TDT analysis (p < 0.05). Moreover,
Tgfb3 was also found among the top 10 genes with differ-
ential expression between endometrial tumors and non-/
pre-malignant endometrium. This result indicates that
Tgfb3 is a susceptibility gene candidate and thus that the
BDII strain might harbor an SNP involved in the initiation
of EAC which will be further investigated. However, the
expression data only correlated with grade of tumor as the
gene was down-regulated in EAC and up-regulated in
Verification of gene expressions by semi-quantitative RT- PCR Figure 3
Verification of gene expressions by semi-quantitative 
RT-PCR. The RT-PCR analysis confirmed down-regulated 
expression of the identified genes in the endometrial tumors. 
The mRNA expressions of Gpx3, Bgn and Tgfb3 are shown 
here. NUT56 and NUT43 are specimens from normal/pre-
malignant endometrium, whereas NUT31 and NUT12 are 
EAC specimens.Cancer Cell International 2009, 9:12 http://www.cancerci.com/content/9/1/12
Page 6 of 9
(page number not for citation purposes)
non-/pre-malignant cell lines regardless of the genetic
background. An explanation for the differences might be
that  Tgfb3  expression is correlated to different genetic
changes occurring during tumor development/progres-
sion. Since TGFβ3 is involved in multiple cellular proc-
esses the effects of genetic variation on mRNA expression
may vary during tumor progression due to interactions
with other affected genes. Thus, if the hypothesized
genetic change in Tgfb3  is inherited, the effect on the
expression level might be different in early and late stages
of EAC.
To investigate whether more specific signature genes that
differentiate between normal/pre-malignant
endometrium and endometrial adenocarcinomas could
be created, we used the classifier tool Weka, which con-
tains a number of different machine learning algorithms.
A majority of the algorithms applied performed very well
in deriving classifiers that could classify the samples
classes, with an average accuracy of 97.1%, and several
algorithms performed at an accuracy of 100%. Depending
on the type of classifier derived, it may or may not be pos-
sible to identify which individual gene was the most
important for the classification result. For example, tree-
based classifiers select a small subset of genes and place
the most important of these at the root of the tree,
whereas multi-layer perceptrons use all genes as input,
and consequently the importance of each gene cannot be
readily determined. In our results, 16 algorithms derived
classifiers where the most important gene could be deter-
mined, and the two genes that were most frequently iden-
tified as top genes in the classifiers were Gpx3  (nine
classifiers) and Bgn (seven classifiers). Based on the con-
tent of these classifiers, Gpx3 and Bgn are the best individ-
ual marker genes and should be investigated for their
potential value in diagnosis of human endometrial aden-
ocarcinoma. The value of Gpx3 and Bgn as signature genes
is strengthened by the fact that both of them are within
the 10 most significant genes in the microarray differen-
tial expression analysis described above.
Plasma glutathione peroxidase, Gpx3, exhibits a critical
role in detoxifying reactive oxidative species and main-
taining the genetic integrity of mammalian cells. Gpx3 has
been found to be either deleted or highly methylated in
exon 1 in prostate cancer cell lines [11,12] and in Barrett's
tumorigenesis [13] and has been suggested to exhibit
tumor suppressor activity. The tumor suppressor activity
of Gpx3  is thought to be associated with its ability to
repress the expression of Met. Expression data of Met in
the present work implies that samples exhibiting an up-
regulation of Gpx3 also show a low expression of Met.
However, additional experimenting is essential to further
evaluate the implications of loss of expression of Gpx3 in
EAC carcinogenesis.
Gene expression of Biglycan, Bgn, is regulated by TGF-β
signaling (dependent on functional smad2 signaling). We
have previously shown down-regulation of several genes
(several of these are among the top 50 genes presented
herein) regulated by the TGF-β signaling pathway, indicat-
ing a disruptive TGF-β signaling. This result further
strengthens our hypothesis of a dysfunctional TGF-β path-
way in rat endometrial tumors. Furthermore, it has been
shown that exogenously administered BGN induced pan-
creatic cancer cells to arrest in the G1 phase of the cell
cycle, indicating a direct inhibiting effect on proliferation
of BGN in cancerous cells [14].
In lung adenocarcinomas, the transcription of Tgfb3 has
been suggested to be stimulated by collagen 1 through the
PI3K/ERK pathway [15]. Our previous results have shown
down-regulation of several pro-collagens [9] which might
explain the decreased mRNA expression of Tgfb3 in our
model. Interestingly, it has been shown that TGFB3
expression is up-regulated in human EAC and that TGFβ-
3 exerts promoting effects on invasiveness [16], which is
contradictive to our results. However, given the back-
ground that Van Themsche and co-workers used two com-
mercial cell lines (i.e. KLE and HEC-1A) originating from
elderly women (64 and 71, respectively), it seems that
they represent the more invasive and non-estrogen
dependent type II endometrial carcinoma, whereas our
model represents estrogen-dependent endometrial carci-
noma. This indicates that TGF-β signaling in the more
aggressive type II endometrial carcinoma has tumor pro-
moting effects, whereas it has been shown that in the
estrogen-dependent type I endometrial carcinoma, the
TGF-β signaling pathway is disrupted [17-19] and thus
has a tumor inhibiting role. Further studies are needed to
clarify the implications of down-regulated expression of
Tgfb3 in rat EAC.
In conclusion, this work provides a unique data set of
genes with distinct expression profiles that may serve as
good candidates for further evaluations of genetic markers
in EAC. Furthermore, by combining three different analy-
sis approaches of the microarray data, we have identified
a three-gene signature that seems to have underlying
implications in EAC carcinogenesis. Table 2 summarizes
the results from combining the three analysis methods for
identifying a prominent EAC gene signature. As rat and
human EAC carcinogenesis is very similar to each other,
both proceeded by hyperplasias, the model can certainly
be used for identifying potential markers and genes prior
to human studies. Thus, we will perform detailed investi-
gations of these three genes in the rat model which ena-
bles future evaluation in corresponding human tumors.
Verification of the rat data in human EACs, and the use of
comparative mapping data between human and rat will
reveal the significance of using this signature for diagnos-Cancer Cell International 2009, 9:12 http://www.cancerci.com/content/9/1/12
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tic and prognostic purposes in human uterine malignan-
cies.
Materials and methods
Animal crosses and tumor material
The animal material was derived from crosses between
BDII/Han females and males from two non-susceptible
rat strains, BN/Han and SPRDCu3/Han, to produce an F1
progeny. Subsequently, an F2 offspring was produced by
brother/sister mating of the F1 progeny and N1 progeny
was produced by backcrossing the males to BDII females.
The female progeny was palpated twice each week for
identification of uterine tumors. Animals suspected to
have tumors were euthanized and the tumor tissue surgi-
cally removed, subjected to pathological characterization
and used to establish cell cultures (for details, see Helou
et al. 2001). Here, we have investigated two groups of
samples, i.e. cell lines established from tissues pathologi-
cally classified as endometrial tumors and cell lines estab-
lished from tissues from normal/pre-malignant
endometrium.
Microarray experiments
The raw expression data of the microarray experiments
were obtained from experiments described in Karlsson et
al. 2007. Briefly, total RNA was extracted from harvested
EAC and non/pre-malignant cell lines and labeled with
Cy3 during cDNA synthesis. Universal rat reference RNA
(Stratagene) was used as a common RNA reference (tran-
scribed and labeled with Cy5) and thus hybridized to all
arrays. We have employed the two-channel cDNA micro-
array format using the 18K (6000 clones in triplicates) rat
70 mer oligonucleotide arrays. The arrays were printed at
the Swegene DNA microarray resource center in Lund,
Sweden, by a BioRobotics MicroGrid 2 arrayer (Cam-
bridge, UK) together with a split pin system. Each probe
in the probe set (Rat 70 mer oligonucleotide set, ver 1.0,
OPERON) was printed in triplicates at random positions
on the arrays. The arrays were scanned in an Agilent
Microarray scanner (Agilent technologies, USA). In total,
45 samples were arrayed. In the present work, we have
focused the analysis on two groups of samples, constitut-
ing 29 arrays. These two groups represent early and more
advanced stages of EAC and were therefore selected for the
analyses in the present work, and is described more in
detail in the discussion [9].
Statistical analysis
The quality control of the GenePix Extraction results was
performed using methods available from Bioconductor
packages (marray, limma, arrayQuality) in the statistical
software package R. Intensities of negative and positive
controls were inspected, as well as spatial effects, M/A
plots and signal-to-noise distributions. No unexpected
results were found, thus indicating an overall high quality
of hybridizations and scanning. Subsequent to image
acquisition and analysis, the microarray data were up-
loaded into the BioArray Software Environment (BASE)
[20] for analysis. The data were cleaned to eliminate bad
quality spots and subsequently print-tip lowess- and scale
normalized. The replicates were merged during the nor-
malization procedures. Spots that were present on less
than 30 arrays (of the total 45) were rejected. The data was
also subjected to variation filtering, i.e. all position-
reporter pairs with standard deviation (SD) smaller than
0.8 were rejected. After cleaning, filtering and normaliza-
tion procedures, 4336 probes/reporters out of 6000
remained. Significant differences in expression for report-
ers between the groups were assessed by applying Stu-
dent's  t  test with a significance threshold of 0.05 and
correction for multiple testing. Comparisons were made
between EAC cell lines vs non/pre-malignant endometrial
cell lines. The p values were adjusted using the False Dis-
covery Rate (FDR) procedure [21].
In the classification analysis, fold change values extracted
from the microarray data were imported into the Waikato
environment for knowledge analysis (Weka, version
3.4.12) [22]. For each of the 28 samples, a "flag" (1 or 0)
was set to signify group membership (cell lines from EAC
tumors and non/pre-malignant lesions, respectively). The
Weka software includes 70 different machine learning
algorithms, each of which can be used to generate a clas-
sifier by learning from examples to distinguish between
groups. We excluded all algorithms requiring discrete-val-
ued input data, since these are not applicable to real-val-
ued gene expression data sets. For each of the remaining
44 algorithms, the 28 samples were repeatedly divided
Table 2: Summary of results from Weka, gene function analysis 
and TDT analysis.
Gene Weka Gene function analysis TDT Analysis
Col1a1 x (4)
Gpx3 xx  ( 1 )
Acta1 x (3)
Serpine1 x (3)
Tgfb3 x (8) x
Wfdc1 x (1)
Bgn xx  ( 1 )
Tgfb1i1 x (2)
Sparc x (1)
Lox x (2)
Thy1 x (10)
Csrp1 x (1)
Bnip3l x (5)
*The numbers within the parentheses denote the frequency of 
cellular functions the gene is involved in.Cancer Cell International 2009, 9:12 http://www.cancerci.com/content/9/1/12
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into a training- and test set, using the leave-one-out cross
validation method [23] and the average classification
accuracy was recorded.
Transmission disequilibrium test (TDT)
TDT statistics for the backcross progeny was performed on
genotype data (Falck et al. manuscript in preparation)
from microsatellite markers located adjacent to chromo-
somal regions harboring the identified classifiers and the
top 50 genes with the most significant differential expres-
sion between the two groups. The TDT statistic for back-
cross progeny is defined as (H-A)2/(H+A), where H is the
number of heterozygous animals and A is the number of
animals homozygous for the BDII allele. The test has a χ2
distribution with one degree of freedom. TDT statistics
were calculated for markers adjacent to each gene in the
EAC tumors versus non/pre-malignant lesions, and for
differences between the two backgrounds, BDII/BN and
BDII/SPRD, respectively.
Gene function classification
A web-accessible program, the Database for Annotation,
Visualization and Integrated Discovery, DAVID, was used
to obtain an overview of the gene functions of the 50
genes with the highest differential expression between
endometrial tumors and non-/pre-malignant
endometrium. DAVID provides tools for functional anno-
tation of genes and gene functional classification, in
which large lists of genes can be rapidly reduced into func-
tionally related groups of genes to help unravel the bio-
logical content. [10] We wanted to investigate whether
these genes were involved in pathways/processes contrib-
uting to the cancer phenotype (increased proliferation,
increased apoptosis etc) and therefore selected cellular
processes typically involved in cancer development.
Validation of the microarray data by semi-quantitative RT-
PCR
Gene expressions for several genes associated with the
TGF-beta pathway (Col1a1, Col1a2, Col3a1, Col5a1, Ltbp2,
Ctgf, Tgfb1i1) were verified in a previous study [9]. In this
study, gene expression changes detected in the microarray
were validated on subset of tumor samples (n = 10) by
semi-quantitative RT-PCR for Tgfb3, Inhba, Wfdc1, Gpx3,
Acta1, Serpine, Cpe, Bgn, Ssg1, Lox1, Bnip3I and  Cnn.
Primer sets specific for these genes were constructed using
the Primer3 program in the Center for Genome Research
at the Whitehead Institute http://frodo.wi.mit.edu/. The
primers were designed to amplify across two or more dif-
ferent exons, thus ruling out DNA amplification. RT-PCR
was performed on 500 ng of total RNA using Omniscript
RT Kit according to the manufacturer's protocol (Qiagen,
UK). Total 500 ng of total RNA was retro-transcribed to
cDNA using 1× RT buffer, 2 mM dNTP mix, 1 μM Oligo-
dT primer, 10 units RNA inhibitor, 4 units Omniscripts
Reverse Transcriptase and RNAse free water for volume
adjustment to 20 μl. PCR Amplification was performed in
a 25 μl reaction mix using 10 μl of the RT reaction. The
running conditions were as follow: 94°C for 2 min, 24–
28 cycles of 30 sec at 94°C, 30 sec at 59°C, and 1 min at
72°C and followed by final extension of 72°C for 5 min.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SK performed the cell culture experiments, microarray
profiling laboratory work, conceived in its design and the
statistical evaluations, the TDT analysis, participated in
the Weka analysis, performed the RT-PCR validations of
the microarray data and drafted the manuscript. BO per-
formed the Weka analysis and helped to draft the manu-
script. KKL was involved in the TDT analysis, the study
design, performed the supervision of the study and helped
in the manuscript preparation. All authors have read and
approved the final version of the manuscript.
Availability and requirements
The microarray data is available at: http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13003
Additional material
Acknowledgements
This work was supported by the Swedish National Research School in Bio-
informatics and Genomics, Erik Philip-Sörensen Foundation, and the Nils-
son-Ehle foundation. We also thank the Swegene DNA Microarray 
Resource center for their exceptional service and support. We are grateful 
to Karin Lilja for excellent technical assistance.
References
1. Gruber SB, Thompson WD: A population-based study of
endometrial cancer and familial risk in younger women.
Cancer and steroid hormone study group.  Cancer Epidemiol
Biomarkers Prev 1996, 5(6):411-417.
2. Prat J: Prognostic parameters of endometrial carcinoma.
Hum Pathol 2004, 35(6):649-662.
3. Bokhman JV: Two pathogenetic types of endometrial carci-
noma.  Gynecologic Oncology 1983, 15:10-17.
4. Deerberg F, Kaspareit J: Endometrial carcinoma in BD II/Han
rats: model of a spontaneous hormone-dependent tumor.  J
Natl Cancer Inst 1987, 78(6):1245-1251.
Additional file 1
The cross-validated average classification results from the Weka anal-
ysis. 16 of the 49 algorithms derived classifiers could determine the most 
important gene for the classification, and the two genes that were most fre-
quently identified as top genes in the classifiers were Gpx3 (nine classifi-
ers) and Bgn (seven classifiers).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-
2867-9-12-S1.doc]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Cancer Cell International 2009, 9:12 http://www.cancerci.com/content/9/1/12
Page 9 of 9
(page number not for citation purposes)
5. Kaspareit-Rittinghausen J, Deerberg F, Rapp K: Mortality and inci-
dence of spontaneous neoplasms in BDII/Han rats.  Z Versuch-
stierkd 1987, 30(5–6):209-216.
6. Vollmer G: Endometrial cancer: experimental models useful
for studies on molecular aspects of endometrial cancer and
carcinogenesis.  Endocr Relat Cancer 2003, 10(1):23-42.
7. Roshani L, Mallon P, Sjostrand E, Wedekind D, Szpirer J, Szpirer C,
Hedrich HJ, Klinga-Levan K: Genetic analysis of susceptibility to
endometrial adenocarcinoma in the BDII rat model.  Cancer
Genet Cytogenet 2005, 158(2):137-141.
8. Roshani L, Wedekind D, Szpirer J, Taib Z, Szpirer C, Beckmann B,
Riviere M, Hedrich HJ, Klinga-Levan K: Genetic identification of
multiple susceptibility genes involved in the development of
endometrial carcinoma in a rat model.  Int J Cancer 2001,
94(6):795-799.
9. Karlsson S, Holmberg E, Askerlund A, Levan KK: Altered trans-
forming growth factor-beta pathway expression pattern in
rat endometrial cancer.  Cancer Genet Cytogenet 2007,
177(1):43-50.
10. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lem-
picki RA: DAVID: Database for Annotation, Visualization, and
Integrated Discovery.  Genome Biol 2003, 4(5):P3.
11. Yu YP, Yu G, Tseng G, Cieply K, Nelson J, Defrances M, Zarnegar R,
Michalopoulos G, Luo JH: Glutathione peroxidase 3, deleted or
methylated in prostate cancer, suppresses prostate cancer
growth and metastasis.  Cancer Res 2007, 67(17):8043-8050.
12. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H:
Functional epigenomics identifies genes frequently silenced
in prostate cancer.  Cancer Res 2005, 65(10):4218-4227.
13. Lee OJ, Schneider-Stock R, McChesney PA, Kuester D, Roessner A,
Vieth M, Moskaluk CA, El-Rifai W: Hypermethylation and loss of
expression of glutathione peroxidase-3 in Barrett's tumori-
genesis.  Neoplasia 2005, 7(9):854-861.
14. Weber CK, Sommer G, Michl P, Fensterer H, Weimer M, Gansauge
F, Leder G, Adler G, Gress TM: Biglycan is overexpressed in pan-
creatic cancer and induces G1-arrest in pancreatic cancer
cell lines.  Gastroenterology 2001, 121(3):657-667.
15. Shintani Y, Maeda M, Chaika N, Johnson KR, Wheelock MJ: Collagen
I promotes epithelial-to-mesenchymal transition in lung can-
cer cells via transforming growth factor-beta signaling.  Am J
Respir Cell Mol Biol 2008, 38(1):95-104.
16. Van Themsche C, Mathieu I, Parent S, Asselin E: Transforming
growth factor-beta3 increases the invasiveness of endome-
trial carcinoma cells through phosphatidylinositol 3-kinase-
dependent up-regulation of X-linked inhibitor of apoptosis
and protein kinase c-dependent induction of matrix metallo-
proteinase-9.  J Biol Chem 2007, 282(7):4794-4802.
17. Gold LI, Parekh TV: Loss of growth regulation by transforming
growth factor-beta (TGF-beta) in human cancers: studies on
endometrial carcinoma.  Semin Reprod Endocrinol 1999,
17(1):73-92.
18. Sakaguchi J, Kyo S, Kanaya T, Maida Y, Hashimoto M, Nakamura M,
Yamada K, Inoue M: Aberrant expression and mutations of
TGF-beta receptor type II gene in endometrial cancer.  Gyne-
col Oncol 2005, 98(3):427-433.
19. Parekh TV, Gama P, Wen X, Demopoulos R, Munger JS, Carcangiu
ML, Reiss M, Gold LI: Transforming growth factor beta signal-
ing is disabled early in human endometrial carcinogenesis
concomitant with loss of growth inhibition.  Cancer Res 2002,
62(10):2778-2790.
20. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A,
Peterson C: BioArray Software Environment (BASE): a plat-
form for comprehensive management and analysis of micro-
array data.  Genome Biol 2002, 3(8):SOFTWARE0003.
21. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a
practical and powerful approach to multiple testing.  Journal of
the Royal Statistical Society Series B 1995, 57:289-300.
22. Frank E, Hall M, Trigg L, Holmes G, Witten IH: Data mining in bio-
informatics using Weka.  Bioinformatics 2004, 20(15):2479-2481.
23. Lachenbruch PaM A: Estimation of error rates in discriminat
analysis.  Techometrics 1968, 10:1-11.